This about as vague a press release I've read, but Gilead must be somewhat confident given that they've paid big bucks to acquire John McHutchison as their Senior Vice President, Liver Disease Therapeutics. More to come as everyone gets a closer look at the data at EASL.
Gilead's hepatitis C therapy called successful
Kristen Hallam, Bloomberg News
Wednesday, March 9, 2011
Gilead Sciences Inc.'s four-drug combination eliminated hepatitis C virus in patients in an early-stage study, RBC Capital Markets LLC analysts said.
The findings support an ongoing midstage study of the combination, the analysts, led by Michael Yee in San Francisco, wrote Monday in a note to investors, citing an abstract of the trial. The analysts said they expect data next year from a midstage study by the Foster City company.
The early-stage study examined a combination of Gilead's GS-9256 and GS-9190 with two older drugs that are the standard of care, ribavirin and Peg-interferon, according to the note.
The data will be presented at the annual meeting of the European Association for the Study of the Liver starting March 30 in Berlin.
Market data provided by Bloomberg News
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment